Literature DB >> 26431299

Randomized Clinical Trial to Compare Micropulse Photocoagulation Versus Half-dose Verteporfin Photodynamic Therapy in the Treatment of Central Serous Chorioretinopathy.

Florian T A Kretz, Isabell Beger, Frank Koch, Katarrzyna Nowomiejska, Gerd U Auffarth, Michael J Koss.   

Abstract

BACKGROUND AND
OBJECTIVE: To evaluate subthreshold diode-laser micropulse (SDM) versus half-dose verteporfin photodynamic therapy (hd-PDT) in central serous chorioretinopathy (CSC). PATIENTS AND METHODS: 62 eyes of 62 patients were prospectively followed for changes in fluorescein angiography (FA), fundus autofluorescence (FAF), central macular thickness (CMT), best-corrected visual acuity (BCVA), and contrast visual acuity (CVA) after SDM (n=20) or hdPDT (n=24). CSC observation served as control group (n=18).
RESULTS: Both treatment groups (60% SDM vs. 66.7% hdPDT) showed significant improvement in reduction of leakage activity compared to the control group (37.5%) at 16 weeks. CMT decreased by 69.7 µm (SDM), 109.8 µm (hdPDT), and 89 µm (control). BCVA improved by +6.7 (SDM group), +8.5 (hdPDT), and +1.5 ETDRS letters (control). CVA was best improved in the hdPDT group. No secondary RPE alterations could be detected by FAF after any intervention.
CONCLUSION: In comparison to the control group, hdPDT and SDM resulted in reduced leakage activity in FA and enhanced photopic and scotopic visual acuity in patients with CSC. Copyright 2015, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26431299     DOI: 10.3928/23258160-20150909-08

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  14 in total

1.  Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy.

Authors:  Brian E Goldhagen; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2017-05-08

Review 2.  Pachychoroid disease spectrum: review article.

Authors:  Thiago José Muniz Machado Mazzeo; Henrique Monteiro Leber; Allan Gomes da Silva; Raimunda Cristina Mendonça Freire; Gabriel Castilho Sandoval Barbosa; Guilherme Garcia Criado; Gabriel Almeida Veiga Jacob; Cleide Guimarães Machado; André Marcelo Vieira Gomes
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-10-14       Impact factor: 3.117

3.  Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents.

Authors:  Benedikt Schworm; Nikolaus Luft; Leonie F Keidel; Felix Hagenau; Christoph Kern; Tina Herold; Karsten U Kortuem; Siegfried G Priglinger; Jakob Siedlecki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-02-28       Impact factor: 3.117

Review 4.  A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders.

Authors:  Paula Scholz; Lebriz Altay; Sascha Fauser
Journal:  Adv Ther       Date:  2017-05-24       Impact factor: 3.845

5.  Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser.

Authors:  Maciej Gawęcki; Agnieszka Jaszczuk-Maciejewska; Anna Jurska-Jaśko; Andrzej Grzybowski
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-22       Impact factor: 3.117

Review 6.  Micropulse Laser Treatment of Retinal Diseases.

Authors:  Maciej Gawęcki
Journal:  J Clin Med       Date:  2019-02-13       Impact factor: 4.241

7.  Efficacy of nanosecond laser treatment in central serous chorioretinopathy with and without atrophy of retinal pigment epithelium.

Authors:  Hakan Kaymak; Saskia Funk; Andreas Fricke; Roxana Fulga; Karsten Klabe; Berthold Seitz; Achim Langenbucher; Hartmut Schwahn
Journal:  Int J Retina Vitreous       Date:  2020-06-04

Review 8.  Management of chronic central serous chorioretinopathy.

Authors:  Daren Hanumunthadu; Anna C S Tan; Sumit Randhir Singh; Niroj Kumar Sahu; Jay Chhablani
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

9.  Transfoveal Micropulse Laser Treatment of Central Serous Chorioretinopathy within Six Months of Disease Onset.

Authors:  Maciej Gawęcki; Agnieszka Jaszczuk-Maciejewska; Anna Jurska-Jaśko; Małgorzata Kneba; Andrzej Grzybowski
Journal:  J Clin Med       Date:  2019-09-06       Impact factor: 4.241

10.  Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy.

Authors:  Zuhua Sun; Ying Huang; Chaochao Nie; Zhijie Wang; Junqing Pei; Bing Lin; Rong Zhou; Junyan Zhang; Victor Chong; Xiaoling Liu
Journal:  Eye (Lond)       Date:  2019-11-29       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.